JP2023507795A - 第XI/XIa因子抗体の医薬製剤および投薬レジメン - Google Patents

第XI/XIa因子抗体の医薬製剤および投薬レジメン Download PDF

Info

Publication number
JP2023507795A
JP2023507795A JP2022538201A JP2022538201A JP2023507795A JP 2023507795 A JP2023507795 A JP 2023507795A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2023507795 A JP2023507795 A JP 2023507795A
Authority
JP
Japan
Prior art keywords
antibody
seq
drug delivery
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507795A5 (cg-RX-API-DMAC7.html
Inventor
デブラ エー. フリードホルム,
ダニエル エム. ブルームフィールド,
ロイストン ジェイ. グラスプール,
ジョナサン イー. フリーマン,
Original Assignee
アントス セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントス セラピューティクス, インコーポレイテッド filed Critical アントス セラピューティクス, インコーポレイテッド
Publication of JP2023507795A publication Critical patent/JP2023507795A/ja
Publication of JP2023507795A5 publication Critical patent/JP2023507795A5/ja
Priority to JP2025207453A priority Critical patent/JP2026048712A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2022538201A 2019-12-20 2020-12-18 第XI/XIa因子抗体の医薬製剤および投薬レジメン Pending JP2023507795A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025207453A JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
US62/951,887 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025207453A Division JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Publications (2)

Publication Number Publication Date
JP2023507795A true JP2023507795A (ja) 2023-02-27
JP2023507795A5 JP2023507795A5 (cg-RX-API-DMAC7.html) 2023-12-15

Family

ID=76478578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538201A Pending JP2023507795A (ja) 2019-12-20 2020-12-18 第XI/XIa因子抗体の医薬製剤および投薬レジメン
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Country Status (9)

Country Link
US (1) US20230071973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076511A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023507795A (cg-RX-API-DMAC7.html)
KR (1) KR20220119090A (cg-RX-API-DMAC7.html)
CN (1) CN115003325A (cg-RX-API-DMAC7.html)
BR (1) BR112022012064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161118A1 (cg-RX-API-DMAC7.html)
IL (1) IL293367A (cg-RX-API-DMAC7.html)
WO (1) WO2021127525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies
EP4461749A4 (en) * 2022-01-05 2025-03-26 Shanghai Mabgen Biotech Ltd. Pharmaceutical composition containing anti-FXI/FXIA antibodies and use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子xi/因子xia抗體之組合療法
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524595A (ja) * 2005-12-20 2009-07-02 ブリストル−マイヤーズ スクイブ カンパニー 安定なタンパク質製剤
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第xi因子抗体および使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
KR102616666B1 (ko) * 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524595A (ja) * 2005-12-20 2009-07-02 ブリストル−マイヤーズ スクイブ カンパニー 安定なタンパク質製剤
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第xi因子抗体および使用方法

Also Published As

Publication number Publication date
BR112022012064A2 (pt) 2022-08-30
IL293367A (en) 2022-07-01
KR20220119090A (ko) 2022-08-26
EP4076511A4 (en) 2024-02-14
US20230071973A1 (en) 2023-03-09
WO2021127525A1 (en) 2021-06-24
EP4076511A1 (en) 2022-10-26
CN115003325A (zh) 2022-09-02
CA3161118A1 (en) 2021-06-24
JP2026048712A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
JP7079844B2 (ja) 高濃度抗c5抗体製剤
US20230071973A1 (en) Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
KR102857973B1 (ko) 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
TW202104270A (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
JP2023527563A (ja) APRIL結合抗体によるIgA腎症を治療する方法
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
JP2021535161A (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
TW202434633A (zh) 治療甲狀腺眼疾之方法
JP2024544057A (ja) 血栓塞栓性疾患を予防及び/又は治療する方法
CN120265653A (zh) 治疗心血管疾病的方法
JP2025523506A (ja) 抗第xi因子/第xia因子抗体との併用療法
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
US20260022197A1 (en) Methods of reversing ticagrelor activity
CN118302196A (zh) 因子XI/XIa抗体的给药方案
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128